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Background and Aims. Hepatic hemangioma (HH) has a widely ranging prevalence. The etiology is unclear; however, associations
with autoimmune disorders have been described. We aimed at evaluating the prevalence of HH in celiac disease.Methods. Ninety-
seven consecutive patients with celiac disease (18M, 79 F,median age 41, and range 17–84 years) underwent liver ultrasound between
January 2011 and 2012. The findings were compared with those of 1352 nonceliac patients (581 M, 771 F, median age 50, and range
16–94 years), without liver disease or previously detected HH, who underwent US in the same period. Results. Ultrasonographic
findings consistent with HH were observed in 14 celiac patients (14.4%), a prevalence significantly higher than in controls (69
cases, 5.1%) (𝑃 = 0.0006). Subgroup analysis showed that, among women, the prevalence of HH was 16.4% in the celiac disease
group (13/79) compared with 5.9% in controls (46/771) (𝑃 = 0.002). In celiac setting, HH had a median diameter of 1.3 cm and
presented as a single lesion in 12 cases (86%). Conclusions. Our findings are consistent with a significantly higher prevalence of HH
in celiac patients. Although mechanisms underlying this association remain unclear, autoimmune and metabolic processes, as well
as alterations of gut-liver axis equilibrium, could play a role.
1. Introduction
Hepatic hemangioma (HH) is the most common benign
mesenchymal hepatic tumor. It has a prevalence ranging
from 3 to 20%. The prevalence is highest in women [1, 2],
and in most cases it is an incidental or autopsy finding [2,
3]. The pathogenesis is far from being clearly understood,
although they are supposed to develop as a consequence of
unregulated angiogenesis [4], influenced by either estrogen
levels [5, 6] or genetic predisposition [7–12]. An association
ofHHwith systemic lupus erythematosus (SLE) has also been
reported, suggesting that HH might be considered a hepatic
manifestation of autoimmune diseases [4].
HHs have never been reported in association with celiac
disease (CD), an immune-mediated enteropathy caused by
permanent immunological intolerance to ingested gluten.
Celiac disease occurs in genetically predisposed people
and affects approximately 1% of the population in Western
countries [13–15]. Many pathological conditions such as
malignancy have been reported as a possible association
with CD [16–22]. Hepatic disorders are common in CD [23,
24] and include steatosis, cryptogenic hypertransaminasemia
[25], and autoimmune liver diseases [26]. Malabsorption
[27], increased intestinal permeability [28, 29], bacterial
overgrowth [30], and intestinal inflammation [31] have been
reported as of relevance in the pathogenesis of liver injury in
CD.
Alteration of the gut-liver axis equilibrium plays a major
role in the development of immune disorders involving
the small bowel and liver [32, 33]. In celiac disease, the
increased intestinal permeabilitymay cause an increased flow
of molecules to the liver through the portal circulation.These
molecules can originate from the local immune reaction
and the cross-linking between tissue transglutaminase and
food or bacterial antigens [34]. There is high probability
that chronic liver exposition to active molecules could lead
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to the development of certain liver diseases. Exposure of
the liver to immunologically active molecules generated in
the small bowel mucosa of CD patients or to high levels
of angiogenic factors, such as vascular endothelial growth
factor (VEGF), could, for instance, lead to the development
of vascular lesions such asHH. An overexpression ofmucosal
VEGF in CD patients, as already suggested in SLE [4], would
be an attractive hypothesis.
As a consequence of previous observations made during
routine clinical practice and based on data collected during a
previous study by our group [35], we developed a hypothesis
that HH could be a frequent finding in patients with CD.
We have performed a retrospective analysis of a consecutive
series of patients, with the aim of evaluating if the prevalence
of HH in a celiac population was higher than that expected in
the general population. This could lead to the underlining of
a possible association with amultifactorial basis betweenHH
and CD.
2. Methods
Thestudywas carried out at theGastroenterology and Endos-
copy Unit, Fondazione IRCCS Ca’ Granda, Ospedale Mag-
giore Policlinico, Milan (Italy).
A series of 97 consecutive patients affected by CD who
were prospectively enrolled for another study by our group
between January 2011 and January 2012 [35] underwent a
complete abdominal ultrasound (US) as part of a thorough
clinical evaluation.
US liver findings were compared with those of a consecu-
tive series of nonceliac patients referred for abdominal US for
unspecific gastrointestinal symptoms (i.e., dyspepsia, abdom-
inal pain, and diarrhea) by our gastroenterology outpatient
clinic during the same period.
All subjects gave their written informed consent to the
study, which was approved by the local ethics committee.
2.1. Patients with CD. Thediagnosis of CDwasmade accord-
ing to currently accepted criteria [36] and was based on
both serology and histology. Anti-endomysial antibodies
were sought using direct immunofluorescence on monkey
esophagus (Bio-Rad, Milan, Italy); positive staining around
the smooth muscle was considered positive. Anti-transglu-
taminase antibodies were assessed by ELISA (Eurospital,
Trieste, Italy); titres above 7 arbitrary units were consid-
ered positive [37, 38]. During upper gastrointestinal tract
endoscopy, four biopsies were taken from the second portion
of the duodenum and the histological diagnosis of CD was
made according to theMarsh classificationmodified byOber-
huber et al. [39, 40]. All CD patients underwent complete
abdominal US and clinical and laboratory parameters were
collected.
2.2. Control Subjects. The control group consisted of consec-
utive nonceliac patients with persistently normal transami-
nases and no known liver diseases, who underwent abdom-
inal US for unspecific gastrointestinal symptoms (i.e., dys-
pepsia, abdominal pain, and diarrhea) during the same
period. Exclusion criteria for both groups included previ-
ously detected HH and/or presence of known liver disease
(including chronic hepatitis B virus and hepatitis C virus
infection, liver cirrhosis, and nonalcoholic steatohepatitis).
For control subjects, additional exclusion criteriawere known
CD or suspected CD, defined as presence of either serological
positivity or pathologic histology at the time of abdominal
US.
2.3. US Studies. Abdominal US examinations were per-
formed after an overnight fast, with a Philips iU22 system
(Philips Ultrasound, Bothell, WA, USA), provided with
a multifrequency convex transducer (C5–2, 5–2MHz). A
complete, standard gray-scale US examination of the upper
abdomen was warranted for all patients. All examinations
were obtained and evaluated in real time by two expert
operators (MF and SM).
2.4. Diagnosis of HH. HHs usually have typical sonographic
features of round-shaped hyperechoic lesions although itmay
appear as a lesion with irregular shape or with hypoechoic
pattern, especially in the context of liver steatosis.
After a first US finding of HH, all patients referred to our
clinic underwent US controls after 3 and 6 months in order
to confirm the diagnosis and to assess stability of shape and
size.
In cases where the sonographic features of the HH find-
ings were not typical, patients underwent further radiological
examination with magnetic resonance (MRI).
2.5. Statistical Analysis. The results are expressed as median
and range, unless otherwise stated. All data were tested
for a normal distribution using the Kolmogoroff-Smirnoff
test. Differences between percentages were evaluated using
Fisher’s exact test. Differences between groupswere evaluated
by means of theMann-Whitney and Kruskal-Wallis tests, fol-
lowed by Dunn’s multiple comparison test when appropriate.
Correlation between variables was assessed by determining
Spearman’s coefficient. A 𝑃 value < 0.05 was considered
statistically significant.
3. Results
Ninety-seven consecutive patients (18 M, 79 F, median age
41, and range 17–84 years) with confirmed CD were included
in the study. Most of them (72, i.e., 74.2%) were on an
ongoing gluten-free diet regimen for a mean period of five
years (range 1–31). A total of 1352 consecutive nonceliac
patients (581 M, 771 F, median age 50, and range 16–94 years)
with persistently normal transaminases and no known liver
diseases were included as control group. Demographic and
clinical characteristics of the study groups are detailed in
Table 1.
In 14 of the 97 celiac patients (14.4%) US findings were
fully consistent with HH, compared with 69 (5.1%) in the
control group (𝑃 = 0.0009).
As detailed in Table 2, HHs in celiac patients had a
median diameter of 1.3 cm (range 0.6–6.8 cm) and presented
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Table 1: Demographic and clinical characteristics in celiac disease
(CD) patients and controls.
CD
(#97)
Controls
(#1352) 𝑃
Age (yrs), median
(range)
41
(17–84)
50.5
(16–94) n.s.
Female, # (%) 79 (81) 771 (57) <0.0001
BMI§ 25–30, # (%) 4 (4.1) 63 (4.7) n.s.
Albumin (g/dL), median
(range)
4.3
(3.8–5.1)
4.6
(4–5.1) n.s.
Steatosis, # (%) 36 (37) 469 (34.6) n.s.
Grades 1, 2, and 3∗ 29, 5, 2 236, 181, 52
§BMI (body mass index) kg/m2.
∗Grade 1: attenuation in the posterior segments of the liver; Grade 2: loss of
echoes from the diaphragm; Grade 3: loss of echoes from the walls of the
portal vein.
Table 2: Characteristics of US findings in celiac disease (CD)
patients and in controls.
CD
(#97)
Controls
(#1352) 𝑃
HH, #
(%)
14
(14.4)
69
(5.1) 0.0009
Prevalence of HH by gender
Females, # (%) 13/79 (16.4) 46/771 (5.9) 0.002
Males, # (%) 1/18 (5.6) 23/581 (3.9) n.s.
Number of lesions
Single, # (%) 12 (85.7) 59 (85.5) n.s.
Multiple, # (%) 2 (14.3) 10 (14.5) n.s.
HH diameter (cm); median
(range)
1.3
(0.3–6.8)
1.5
(0.7–4.6) n.s.
Atypical features∗, # (%) 1 (1) 11 (0.81) n.s.
HH: hepatic hemangioma.
∗Hypoechoic or isoechoic lesions, mixed echogenicity, lobulated mass, and
blurred margins.
as a single lesion in 12 of the 14 patients (86%). They
appeared as hyperechoic lesions in 13 patients (93%), without
significant differences from the US findings in the control
group, where the median diameter was 1.5 cm (range 0.7–4.6)
and the lesion was single in 59 cases (86%). In cases where
the sonographic features of the HH findings were not typical
(i.e., atypical shape, hypoechoic pattern), patients underwent
further radiological examination with magnetic resonance
(MRI), which confirmed the diagnosis (1 patient in the CD
group and 11 patients in the control group).
The prevalence of female gender was higher in CD than
in the control population (𝑃 < 0.0001). The two groups were
indeed similar in regard to age and presence of steatosis (the
latter was present in 37% of CD patients versus 34.6% of
control subjects, 𝑃 = n.s.).
The prevalence of HH was 5.6% in male celiac patients
(1/18) compared with 3.9% in nonceliac patients (23/581)
(𝑃 = n.s.). Among women, the prevalence was 16.4% in
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Figure 1: Prevalence of hepatic hemangioma (HH) in female CD
patients and in female control subjects. 𝑦-axis: female control
subjects and female CD patients; 𝑥-axis: number of subjects.
the CD group (13/79) versus 5.9% in the control group
(46/771) (Figure 1, 𝑃 = 0.002).
4. Discussion
Results from this series suggest a higher HH prevalence in
CD than in controls, delineating a previously unreported
association. Indeed, the prevalence of HH at US liver scan
was about three times higher in CD than in controls, the
difference being even higher in women.
This study represents the first series aimed at evaluating
the possible association between HH and CD. In this context,
it is of relevance that both the large control group and
the inclusion and exclusion criteria make this group highly
representative of the general population. Firstly, patients
with existing liver disease were excluded from the study
because the sonographic diagnosis of HH would have been
extremely difficult in this specific setting, requiring more
than one imaging technique to avoid a misdiagnosis of liver
malignancy. Additionally, patients with already known HH
were excluded, due to the risk of bias from extremely high
prevalence of patients with known focal liver lesions referred
to our tertiary center for consultation and repeat US scans.
Excluding these patients, the observed prevalence of 5.1% of
US findings of HH in the control group is consistent with
epidemiological data in the general population [1–3].
A point of weakness of this series is the relatively small
number ofmale subjects in theCDgroup. In fact, both groups
had a higher prevalence of female subjects, particularly
relevant in the CD group (79 versus 18), reflecting the higher
prevalence of the disease in females [41, 42]. The finding of
only one HH among the 18 male CD patients precludes any
conclusions. This suggests the need for collecting a larger
number of male CD patients in future series, to both improve
the statistical power of US findings and help in clarifying the
potential influence of estrogen.
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A second aspect of weakness is that at present MRI is
generally considered the reference standard for detecting
HH. In this study MRI was actually performed only when
facing large HHs or lesions with atypical features. There are
conflicting recommendations regarding the management of
patients with US findings consistent with “typical” HH and
it is a matter of discussion whether the diagnostic accuracy
of US is sufficient for a correct diagnosis of HH, mainly in
the setting of patients with liver steatosis, which was detected
in more than one-third of CD patients and controls. Aiming
at increasing the diagnostic performance of US liver scan, US
examinations were performed by two operators (MF and SM)
with large experience in the field.
Another point to consider is the prevalence of single HH
at US. In both CD patients and controls HH was detected
as a single lesion in nearly 86% of the cases. It is commonly
believed that HH is often solitary, but available data support
the hypothesis that multiple lesions could be present in up to
40% of patients [1, 2]. However, as scattered data are available
about theUS detection rate ofmultiple versus single lesions, a
14% rate of detection of multiple HH in both groups, without
a significant difference, suggests a satisfying accuracy for this
imaging technique.
The mechanisms underlying the possible association
between HH and CD are still far from clearly understood.
However, hormonal, autoimmune, genetic and metabolic
processes could play a role.
Firstly, HH and CD are known to be more common in
females. This could partially explain the association of CD
and HH detected in our study, suggesting a potential role
of estrogen as triggering factor. However, we also observed
an increased prevalence of HH in the CD male group (5.6%
versus 3.9%), although the data did not reach statistical
significance. Moreover, estrogen receptors have not been
found in all HHs, and hemangioma growthmay also occur in
postmenopausal women, independent of hormonal influence
[3].
Secondly, Berzigotti et al. reported fivefold increased
odds of HH in a series of SLE patients, suggesting that HH
might be considered among the hepatic manifestations of
SLE [4]. Since SLE is considered an autoimmune disorder,
as is CD, autoimmunity could also play an important role.
However, the exact autoimmune mechanisms potentially
involved remain to be elucidated.
Moreover, as already suggested in SLE [4], an overexpres-
sion of angiogenic factors, particularly vascular endothelial
growth factor (VEGF), in CD patients would be an attractive
hypothesis even if further studies are needed in this context.
It has been suggested that hemangiomas could be related to
a dysregulated angiogenesis due to an imbalance between
angiogenic and angiostatic factors [43]. The alteration of
gut-liver axis equilibrium due to the increased intestinal
permeability in CD may cause a flow of active molecules
to the liver through the portal circulation [34]. Liver expo-
sure to high levels of angiogenic factors could lead to the
development of vascular lesions. However, in this study, data
supporting this hypothesis are lacking, because blood and
mucosal VEGF and other proangiogenic cytokines were not
determined. Kitajima et al. [44] studied a transgenic rabbit
model with increased liver expression of the human VEGF,
whose upregulation has already been reported in association
with hemangiomas. In that study, the overexpression of
VEGF in the liver was determined to be sufficient for induc-
ing hemangiomas. Moreover, transgenic rabbits developed
hemolytic anemia, thrombocytopenia, and splenomegaly, all
possible features of genetic syndromes such as Kasabach-
Merrit syndrome [7]; thus, the above model could be useful
in elucidating the mechanism underlying the development of
HH and related complications.
Finally, another possible explanation could be a com-
mon genetic pathway, since familial or genetic patterns of
inheritance have been hypothesized in both CD and HH. CD
usually develops in genetically predisposed patients, with a
strong association with HLA-DQ genes [13]. On the other
hand, HHs have been described as part of defined clinical
syndrome and, according to some authors, hemangiomas
may be indicators of serious syndromes. However, no patient
included in this study was affected by a genetic syndrome.
5. Conclusions
Overall, as from our data, HH prevalence seems to be signif-
icantly higher in CD patients than in the general population.
Further studies are needed both to confirm this data and to
explain the possible pathogenetic pathways, before suggesting
that all patients with US findings consistent with HH should
be screened for CD.
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